SF3971

Summary

A Minnesota bill to establish a psilocybin therapeutic use program has had an additional author added and remains in the early legislative stage. Creation of a regulated psilocybin therapeutic program could open a new licensed market with testing and compliance requirements relevant to laboratories and specialized operators.

More Minnesota Cannabis Bills

• SF4401Omnibus Cannabis billPassed
• SF4957Registered designated caregivers provisions modifications and increasing patient and cannabis plant limits expansion provisionIntroduced
• HF3615Cannabis laboratory testing requirements extended.Passed
• SF4877Cannabis license application periods and issuance modificationIntroduced
• SF4871Remediated cannabis product definitionIntroduced
• SF4876Cannabis microbusiness outdoor cultivation limit increaseIntroduced
• HF4733Remediated cannabis product defined, and cannabis business required to disclose information related to remediated cannabis products.Introduced
• SF4875Medical cannabis endorsement requirements modificationIntroduced
• HF4688Cannabis license holders allowed to transport products to testing facilities.Introduced
• HF4577Psilocybin therapeutic use program established; protections for registered patients, registered suppliers, registered facilitators, and health care practitioners established; civil actions authorized; advisory committee established; and money appropriated.Introduced
• HF4570Cannabis microbusiness outdoor cultivation limit increased.Introduced
• SF4542Cannabis event provisions modificationIntroduced